Atazanavir (Page 2 of 12)

2.6 Dosage Adjustments in Pregnant Patients

Table 4 includes the recommended dosage of atazanavir capsules and ritonavir in treatment-naive and treatment-experienced pregnant patients. In these patients, atazanavir capsules must be administered with ritonavir. There are no dosage adjustments for postpartum patients (see Table 1 for the recommended atazanavir capsules dosage in adults) [see Use in Specific Populations (8.1)].

Table 4: Recommended Dosage of Atazanavir Capsules and Ritonavir in Pregnant Patientsa

Atazanavir Capsules

Once Daily

Dosage

Ritonavir

Once Daily

Dosage

Treatment-Naive and Treatment-Experienced

Recommended Regimen

300 mg

100 mg

Treatment-Experienced During the Second or Third Trimester When Co-administered with either H2RA or Tenofovir DFb

In combination with EITHER H2RA OR tenofovir DF

400 mg

100 mg

a See Drug Interactions (7) for instructions concerning co-administration of acid-reducing medications (e.g., H2RA or PPIs), and other antiretroviral drugs (e.g., efavirenz, tenofovir DF, and didanosine).

b Atazanavir capsules are not recommended for treatment-experienced pregnant patients during the second and third trimester taking atazanavir with BOTH tenofovir DF and H2RA.

2.7 Dosage in Patients with Renal Impairment

For patients with renal impairment, including those with severe renal impairment who are not managed with hemodialysis, no dose adjustment is required for atazanavir capsules. Treatment-naive patients with end-stage renal disease managed with hemodialysis should receive atazanavir capsules 300 mg with ritonavir 100 mg. Atazanavir capsules are not recommended in treatment-experienced patients with HIV-1 infection who have end-stage renal disease managed with hemodialysis [see Use in Specific Populations (8.7)].

2.8 Dosage Adjustments in Patients with Hepatic Impairment

Table 5 displays the recommended atazanavir capsules dosage in treatment-naive patients with hepatic impairment. The use of atazanavir capsules in patients with severe hepatic impairment (Child-Pugh Class C) is not recommended. The co-administration of atazanavir capsules with ritonavir in patients with any degree of hepatic impairment is not recommended.

Table 5: Recommended Dosage of Atazanavir Capsules in Treatment-Naive Adults with Hepatic Impairment

Atazanavir Capsules

Once Daily Dosage

Mild hepatic impairment (Child-Pugh Class A)

400 mg

Moderate hepatic impairment (Child-Pugh Class B)

300 mg

Severe hepatic impairment (Child-Pugh Class C)

Atazanavir capsules with or without ritonavir is not recommended

3 DOSAGE FORMS AND STRENGTHS

Atazanavir Capsules:

  • Atazanavir capsules, 100 mg are size ‘2’ hard gelatin capsules having imprinted ‘Amneal 100 mg’ on blue opaque cap with white ink and ‘1135’ on white opaque body with blue ink, filled with off-white to yellow granular powder.
  • Atazanavir capsules, 150 mg are size ‘1’ hard gelatin capsules having imprinted ‘Amneal 150 mg’ on blue opaque cap with white ink and ‘1136’ on powder blue opaque body with blue ink, filled with off-white to yellow granular powder.
  • Atazanavir capsules, 200 mg are size ‘0’ hard gelatin capsules having imprinted ‘Amneal 200 mg’ on blue opaque cap and ‘1137’on blue opaque body with white ink, filled with off-white to yellow granular powder.
  • Atazanavir capsules, 300 mg are size ‘00’ hard gelatin capsules having imprinted ‘Amneal 300 mg’ on red opaque cap and ‘1138’ on blue opaque body with white ink, filled with off-white to yellow granular powder.

4 CONTRAINDICATIONS

Atazanavir capsules are contraindicated:

  • in patients with previously demonstrated clinically significant hypersensitivity (e.g., Stevens-Johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of atazanavir capsules [see Warnings and Precautions (5.2)].
  • when co-administered with drugs that are highly dependent on CYP3A or UGT1A1 for clearance, and for which elevated plasma concentrations of the interacting drugs are associated with serious and/or life-threatening events (see Table 6).
  • when co-administered with drugs that strongly induce CYP3A and may lead to lower exposure and loss of efficacy of atazanavir (see Table 6).

Table 6 displays drugs that are contraindicated with atazanavir.

Table 6: Drugs Contraindicated with Atazanavir (Information in the table applies to Atazanavir with or without ritonavir, unless otherwise indicated)

Drug Class

Drugs within class that are contraindicated with atazanavir

Alpha 1-adrenoreceptor antagonist

Alfuzosin

Antiarrhythmics

Amiodarone (with ritonavir), quinidine (with ritonavir)

Antimycobacterials

Rifampin

Antineoplastics

Irinotecan

Antipsychotics

Lurasidone (with ritonavir), pimozide

Benzodiazepines

Triazolam, orally administered midazolama

Ergot Derivatives

Dihydroergotamine, ergotamine, ergonovine, methylergonovine

GI Motility Agent

Cisapride

Hepatitis C Direct-Acting Antivirals

Elbasvir/grazoprevir; glecaprevir/pibrentasvir

Herbal Products

St. John’s wort (Hypericum perforatum)

Lipid-Modifying Agents:

Lovastatin, simvastatin, lomitapide

Phosphodiesterase-5 (PDE-5) Inhibitor

Sildenafilb when dosed as REVATIO® for the treatment of pulmonary arterial hypertension

Protease Inhibitors

Indinavir

Non-nucleoside Reverse Transcriptase Inhibitors

Nevirapine

a See Drug Interactions, Table 16 (7) for parenterally administered midazolam.

b See Drug Interactions, Table 16 (7) for sildenafil when dosed as VIAGRA® for erectile dysfunction.

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2021. All Rights Reserved.